Table 3.
Minor amino acid substitutions associated with drug resistance in newly diagnosed ART-naive HIV-infected adults in Taizhou, 2008–2011
| Mutation | No. and proportion (%) of patients with amino acid substitutions | χ2 | P | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CRF01_AE (n = 240) | CRF07_BC (n = 90) | CRF08_BC (n = 52) | B (n = 56) | C (n = 8) | A (n = 1) | Total (N = 447) | |||
| Protease gene | |||||||||
| L10I/V/F | 9 (3·8) | 6 (6·7) | 3 (5·4) | 1 (100·0) | 19 (4·3) | 11·62 | 0·037 | ||
| G16E | 30 (12·5) | 30 (6·7) | 29·84 | 0·000 | |||||
| K20I/R | 78 (32·5) | 5 (5·6) | 2 (3·6) | 85 (19·0) | 68·29 | 0·000 | |||
| L33I/F | 3 (1·3) | 3 (0·7) | 5·67 | 0·825 | |||||
| M36I | 228 (95·0) | 5 (5·6) | 26 (50·0) | 2 (3·6) | 7 (87·5) | 1 (100·0) | 269 (60·2) | 365·81 | 0·000 |
| M46I | 2 (0·8) | 2 (0·4) | 6·44 | 1·000 | |||||
| L63P | 40 (16·7) | 83 (92·2) | 47 (90·4) | 44 (78·6) | 2 (25·0) | 216 (48·3) | 249·74 | 0·000 | |
| A71 T/V | 12 (13·3) | 1 (1·9) | 16 (28·6) | 29 (6·5) | 63·36 | 0·000 | |||
| V77I | 13 (5·4) | 24 (26·6) | 51 (91·1) | 88 (19·7) | 198·91 | 0·000 | |||
| V82A | 1 (1·1) | 1 (0·2) | 10·61 | 0·463 | |||||
| L90M | 1 (1·8) | 1 (0·2) | 11·56 | 0·262 | |||||
| I93L | 108 (45·0) | 80 (88·9) | 52 (100·0) | 46 (82·1) | 8 (100·0) | 294 (65·8) | 120·59 | 0·000 | |
| Reverse transcriptase gene | |||||||||
| A62 V | 3 (5·8) | 3 (0·7) | 14·94 | 0·009 | |||||
| T69N/S | 6 (11·5) | 6 (1·3) | 24·84 | 0·000 | |||||
| V90I | 1 (0·4) | 1 (0·2) | 8·64 | 1·000 | |||||
| K103N | 1 (1·8) | 1 (0·2) | 11·56 | 0·262 | |||||
| V108I | 1 (0·4) | 4 (50·0) | 5 (1·1) | 31·35 | 0·000 | ||||
| E138G | 1 (1·1) | 1 (0·2) | 10·61 | 0·463 | |||||
| V179D/E | 8 (3·3) | 5 (9·6) | 3 (5·4) | 16 (3·5) | 10·86 | 0·052 | |||
| M184 V | 1 (0·4) | 1 (0·2) | 8·64 | 1·000 | |||||
| Y188I | 1 (1·8) | 1 (0·2) | 11·56 | 0·262 | |||||
| G190A | 1 (1·8) | 1 (0·2) | 11·56 | 0·262 | |||||
| T215S | 1 (0·4) | 2 (3·6) | 3 (0·7) | 9·31 | 0·192 | ||||